Indication
Metastatic Head and Neck Squamous Cell Cancer
1 clinical trial
2 products
Clinical trial
A Phase 1 Study of Concurrent Cabozantinib and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
CabozantinibProduct
Cetuximab